Table 1.
Characteristics of 140 Healthy Study Participants.
| Characteristic | Antibody Concentration, BAU/mL, Median (IQR) | |
|---|---|---|
| Age, median (range) | 55 (20–89) | |
| Sex (n) | ||
| Male (%) | 46 (32.9) | |
| Female (%) | 94 (67.1) | |
| Vaccine Received (n) | ||
| FIRST DOSE | ||
| BNT162b2 | 37 | 120.8 (81.9–216.0) |
| AZD1222 | 20 | 107.2 (55.1–192.5) |
| mRNA-1273 | 6 | 1096.8 (410.8–1877.8) |
| Median antibody concentration for all vaccines (n and median) | 63 | 143.6 (79.0–266.6) |
| Days between 1st dose and blood collection, mean (SD) | 62.8 (±28.4) | |
| Days between 1st and 2nd dose, mean (SD) |
77.1 (±25.9) | |
| SECOND DOSE | ||
| BNT162b2 | 40 | 1245.2 (475.2–1951.5) |
| Mixed | 70 | 1146.6 (634.5–1760.1) |
| AZD1222 | 11 | 188.4 (88.6–279.1) |
| mRNA-1273 | 4 | 1731.3 (820.6–3541.2) |
| Median antibody concentration for all vaccines (n and median) | 126 | 1046.4 (423.9–1738.2) |
| Days between 2nd dose and blood collection, mean (SD) | 72.7 (±51.4) | |
| Days between 2nd and 3rd dose, mean (SD) |
179.8 (±42.5) | |
| THIRD DOSE | ||
| BNT162b2 | 24 | 1570.5 (985.7–3765.4) |
| Mixed | 50 | 1559.1 (627.8–3561.3) |
| AZD1222 | 0 | NA |
| mRNA-1273 | 2 | 4265.4 (2959.7–5571.2) |
| Median antibody concentration for all vaccines (n and median) | 79 | 1604.7 (700.1–3764.0) |
| Days between 3rd dose and blood collection, mean (SD) | 135.8 (±35.1) | |
| p value * | <0.001 |
* p < 0.001 when comparing the antibody concentration between the median antibody concentration of the three doses.